Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, the following:
? our dependence on product candidates, which are still in an early development stage;
? our ability to successfully complete research and further development, including preclinical and clinical studies, and, if we obtain regulatory approval, commercialization of our drug candidates and the growth of the markets for those drug candidates;
? our anticipated timing for preclinical development, regulatory submissions, commencement and completion of clinical trials and product approvals;
? the impact of the COVID-19 pandemic on our business or on the economy generally;
- 6 -
? whether the COVID-19 pandemic will affect the timing of the completion of our planned and/or currently ongoing preclinical/clinical trials;
? our ability to negotiate strategic partnerships, where appropriate, for our drug candidates;
? our ability to manage multiple clinical trials for a variety of drug candidates at different stages of development;
? the cost, timing, scope and results of ongoing preclinical and clinical testing;
? our expectations of the attributes of our product and development candidates, including pharmaceutical properties, efficacy, safety and dosing regimens;
? the cost, timing, and uncertainty of obtaining regulatory approvals for our drug candidates;
? the availability, cost, delivery, and quality of clinical management services provided by our clinical research organization partners;
? the availability, cost, delivery, and quality of clinical and commercial-grade materials produced by our own manufacturing facility or supplied by contract manufacturers, suppliers and partners;
? our ability to develop and commercialize products before competitors that are superior to the alternatives developed by such competitors;
? our ability to develop technological capabilities, including identification of novel and clinically important targets, exploiting our existing technology platforms to develop new drug candidates and expand our focus to broader markets for our existing targeted therapeutics;
? the cost of paying development, regulatory approval and sales-based milestones under future acquisition agreements;
? our ability to realize the anticipated benefits from the sale of products;
? our ability to raise sufficient capital to fund our preclinical and clinical studies and to meet our long-term liquidity needs, on terms acceptable to us, or at all. If we are unable to raise the funds necessary to meet our long-term liquidity needs, we may have to delay or discontinue the development of one or more programs, discontinue or delay ongoing or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or part of our business;
? our ability to protect our intellectual property rights and our ability to avoid intellectual property litigation, which can be costly and divert management time and attention; and our ability to develop and commercialize products without infringing the intellectual property rights of third parties. The forward-looking statements in this Offering Circular are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those presented in the forward-looking statements.
